HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use LEVETIRACETAM INJECTION safely and effectively. See full prescribing information for LEVETIRACETAM INJECTION. LEVETIRACETAM injection, for intravenous use Initial U.S. Approval: 1999 RECENT MAJOR CHANGES
INDICATIONS AND USAGE
DOSAGE AND ADMINISTRATIONLevetiracetam injection is for intravenous use only (2.1) Partial-Onset Seizures (monotherapy or adjunctive therapy)
Myoclonic Seizures in Adults and Pediatric Patients 12 Years and Older
Primary Generalized Tonic-Clonic Seizures
Switching From or To Oral Levetiracetam When switching from or to oral levetiracetam, the total daily dosage/frequency of Levetiracetam injection should be equivalent to those of oral Levetiracetam. (2.4, 2.5) See full prescribing information for preparation and administration instructions (2.6) and dosage adjustment in adults with renal impairment. (2.7) DOSAGE FORMS AND STRENGTHSInjection: 500 mg/5 mL single-dose vial. (3) CONTRAINDICATIONSWARNINGS AND PRECAUTIONS
ADVERSE REACTIONSMost common adverse reactions (incidence ≥ 5% more than placebo) include:
To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. USE IN SPECIFIC POPULATIONSPregnancy: Plasma levels of levetiracetam may be decreased; monitor closely during pregnancy. Based on animal data, may cause fetal harm. (5.10, 8.1) See 17 for PATIENT COUNSELING INFORMATION. Revised: 5/2024 |
HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use LEVETIRACETAM INJECTION safely and effectively. See full prescribing information for LEVETIRACETAM INJECTION. LEVETIRACETAM injection, for intravenous use Initial U.S. Approval: 1999 RECENT MAJOR CHANGES
INDICATIONS AND USAGE
DOSAGE AND ADMINISTRATIONLevetiracetam injection is for intravenous use only (2.1) Partial-Onset Seizures (monotherapy or adjunctive therapy)
Myoclonic Seizures in Adults and Pediatric Patients 12 Years and Older
Primary Generalized Tonic-Clonic Seizures
Switching From or To Oral Levetiracetam When switching from or to oral levetiracetam, the total daily dosage/frequency of Levetiracetam injection should be equivalent to those of oral Levetiracetam. (2.4, 2.5) See full prescribing information for preparation and administration instructions (2.6) and dosage adjustment in adults with renal impairment. (2.7) DOSAGE FORMS AND STRENGTHSInjection: 500 mg/5 mL single-dose vial. (3) CONTRAINDICATIONSWARNINGS AND PRECAUTIONS
ADVERSE REACTIONSMost common adverse reactions (incidence ≥ 5% more than placebo) include:
To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. USE IN SPECIFIC POPULATIONSPregnancy: Plasma levels of levetiracetam may be decreased; monitor closely during pregnancy. Based on animal data, may cause fetal harm. (5.10, 8.1) See 17 for PATIENT COUNSELING INFORMATION. Revised: 5/2024 |
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.